MCID: OPN001
MIFTS: 55

Open-Angle Glaucoma

Categories: Eye diseases, Genetic diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Open-Angle Glaucoma

MalaCards integrated aliases for Open-Angle Glaucoma:

Name: Open-Angle Glaucoma 12 15 17
Glaucoma, Open-Angle 44 70
Open Angle Glaucoma 12 6
Pigmentary Glaucoma 12
Wide-Angle Glaucoma 12
Glaucoma Open-Angle 54
Glaucoma Simplex 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1067
ICD9CM 34 365.1
MeSH 44 D005902
NCIt 50 C34641
SNOMED-CT 67 84494001
ICD10 32 H40.1
UMLS 70 C0017612

Summaries for Open-Angle Glaucoma

Disease Ontology : 12 A glaucoma characterized by optic nerve damage resulting in progressive loss of visual field and increased pressure in the eye due to trabecular blockage.

MalaCards based summary : Open-Angle Glaucoma, also known as glaucoma, open-angle, is related to glaucoma 1, open angle, a and glaucoma, primary open angle. An important gene associated with Open-Angle Glaucoma is MYOC (Myocilin), and among its related pathways/superpathways are Degradation of the extracellular matrix and Elastic fibre formation. The drugs Trimethoprim and Polymyxin B have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and endothelial, and related phenotype is vision/eye.

Related Diseases for Open-Angle Glaucoma

Diseases in the Open-Angle Glaucoma family:

Glaucoma 1, Open Angle, a Glaucoma, Primary Open Angle
Glaucoma 1, Open Angle, P Glaucoma 1, Primary Open Angle, C
Glaucoma 1, Open Angle, D Glaucoma 1, Open Angle, F
Glaucoma 1, Open Angle, B Glaucoma 1, Open Angle, J
Glaucoma 1, Open Angle, K Glaucoma 1, Open Angle, I
Glaucoma 1, Open Angle, G Glaucoma 1, Open Angle, M
Glaucoma 1, Open Angle, N Glaucoma 1, Open Angle, H
Glaucoma 1, Open Angle, O

Diseases related to Open-Angle Glaucoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 385)
# Related Disease Score Top Affiliating Genes
1 glaucoma 1, open angle, a 33.6 OPTN MYOC CYP1B1
2 glaucoma, primary open angle 33.3 WDR36 TMCO1 TGFB2 TBK1 OPTN OPTC
3 intraocular pressure quantitative trait locus 33.1 WDR36 TMCO1 TGFB2 OPTN OPA1 MYOC
4 early-onset glaucoma 32.9 MYOC CYP1B1
5 exfoliation syndrome 32.9 MMP1 LTBP2 LOXL1 GSTM1 ELN
6 ocular hypertension 32.6 WDR36 TMCO1 TGFB2 OPTN MYOC CRYAA
7 glaucoma, normal tension 32.6 WDR36 TMCO1 TBK1 OPTN OPTC OPA1
8 juvenile glaucoma 32.6 WDR36 OPTN MYOC LTBP2 LOXL1 CYP1B1
9 axenfeld-rieger syndrome 32.4 WDR36 MYOC LTBP2 LMX1B CYP1B1 CRYAA
10 optic nerve disease 32.1 WDR36 OPTN OPA1 MYOC ELN CRYAA
11 myopia 32.0 WDR36 TGFB2 OPTC MYOC MMP1 LTBP2
12 primary angle-closure glaucoma 32.0 OPTN MYOC CYP1B1
13 glaucoma 1, open angle, d 31.7 OPTN MYOC LTBP2 LOC108903148 CYP1B1 CARD10
14 eye disease 31.6 TGFB2 OPTN MYOC MMP1 CYP1B1 CRYAA
15 primary congenital glaucoma 31.6 WDR36 OPTN NTF4 MYOC LTBP2 LOXL1
16 chronic closed-angle glaucoma 31.6 TGFB2 MYOC LOXL1
17 glaucoma 3, primary congenital, a 31.5 WDR36 OPTN MYOC LTBP2 CYP1B1
18 corneal edema 31.4 MYOC MMP1 LTBP2 CYP1B1
19 neovascular glaucoma 31.3 TGFB2 MYOC CRYAA
20 macular degeneration, age-related, 1 31.2 TGFB2 OPTC MYOC LOXL1 ELN CRYAA
21 glaucoma-related pigment dispersion syndrome 31.2 WDR36 TMCO1 OPTN MYOC LOXL1 LMX1B
22 steroid-induced glaucoma 31.1 WDR36 TGFB2 MYOC ELN CYP1B1 CRYAA
23 leber hereditary optic neuropathy, modifier of 31.0 WDR36 OPA1 MYOC CRYAA
24 megalocornea 31.0 WDR36 MYOC LTBP2 CYP1B1
25 keratitis, hereditary 30.9 MYOC LMX1B CYP1B1 CRYAA
26 amyotrophic lateral sclerosis type 12 30.8 OPTN LOC108903148 CRYAA
27 amyotrophic lateral sclerosis 12 with or without frontotemporal dementia 30.8 OPTN LOC108903148
28 lens subluxation 30.8 LTBP2 LOXL1 CRYAA
29 acute closed-angle glaucoma 30.8 OPTN MYOC CYP1B1
30 traumatic glaucoma 30.8 TMCO1 MYOC LTBP2 LOXL1 CYP1B1
31 macular holes 30.7 TGFB2 OPTC CRYAA
32 retinal disease 30.7 OPTN OPTC MYOC CRYAA
33 glaucoma 3, primary infantile, b 30.7 LTBP2 CYP1B1
34 anterior segment dysgenesis 30.5 WDR36 TMCO1 MYOC LTBP2 LMX1B CYP1B1
35 marfan syndrome 30.5 TGFB2 MMP1 LTBP2 LOXL1 ELN
36 iris disease 30.5 WDR36 MYOC LTBP2 LOXL1 ELN CYP1B1
37 retinal vascular occlusion 30.3 OPTC LOXL1 CRYAA
38 glaucoma 1, open angle, p 11.7
39 glaucoma 1, open angle, f 11.7
40 residual stage of open angle glaucoma 11.6
41 glaucoma 1, open angle, g 11.6
42 glaucoma 1, open angle, o 11.6
43 yemenite deaf-blind hypopigmentation syndrome 11.2
44 phacolytic glaucoma 11.2
45 cataract 11.1
46 refractive error 10.9
47 neuropathy 10.7
48 scotoma 10.6
49 uveitis 10.6
50 retinal vascular disease 10.6

Comorbidity relations with Open-Angle Glaucoma via Phenotypic Disease Network (PDN):


Anatomical Narrow Angle Borderline Glaucoma Glaucoma, Primary Open Angle
Hypertension, Essential Ocular Hypotension

Graphical network of the top 20 diseases related to Open-Angle Glaucoma:



Diseases related to Open-Angle Glaucoma

Symptoms & Phenotypes for Open-Angle Glaucoma

MGI Mouse Phenotypes related to Open-Angle Glaucoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 vision/eye MP:0005391 9.28 CYP1B1 LMX1B LOXL1 LTBP2 MYOC OPA1

Drugs & Therapeutics for Open-Angle Glaucoma

Drugs for Open-Angle Glaucoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 209)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
2
Polymyxin B Approved, Vet_approved Phase 4 1404-26-8
3
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
4
Bimatoprost Approved, Investigational Phase 4 155206-00-1 5311027
5
Tobramycin Approved, Investigational Phase 4 32986-56-4 5496 36294
6
Apraclonidine Approved Phase 4 66711-21-5 2216
7
Sorbitol Approved Phase 4 50-70-4 5780
8
Loteprednol Approved, Experimental Phase 4 129260-79-3, 82034-46-6 444025 9865442
9
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
10
Fluorouracil Approved Phase 4 51-21-8 3385
11
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
12
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
13
Cefuroxime Approved Phase 4 55268-75-2 5361202 5479529
14
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
15
tannic acid Approved Phase 4 1401-55-4
16
Brinzolamide Approved Phase 4 138890-62-7 68844
17
Dorzolamide Approved Phase 4 120279-96-1 3154 5284549
18
Bevacizumab Approved, Investigational Phase 4 216974-75-3
19
Lutein Approved, Investigational, Nutraceutical Phase 4 127-40-2 5281243
20
Maleic acid Experimental Phase 4 110-16-7 444266
21 Polymyxins Phase 4
22 Anti-Infective Agents, Local Phase 4
23 Benzalkonium Compounds Phase 4
24 Brimonidine Tartrate, Timolol Maleate Drug Combination Phase 4
25 Respiratory System Agents Phase 4
26 Anti-Asthmatic Agents Phase 4
27 Dermatologic Agents Phase 4
28 Anti-Allergic Agents Phase 4
29 Bronchodilator Agents Phase 4
30 Dextrans Phase 4
31 Plasma Substitutes Phase 4
32 Blood Substitutes Phase 4
33 Anticoagulants Phase 4
34 Immunologic Factors Phase 4
35 Hormones Phase 4
36 Immunosuppressive Agents Phase 4
37 Hormone Antagonists Phase 4
38 glucocorticoids Phase 4
39 Anti-Inflammatory Agents Phase 4
40 Antimetabolites Phase 4
41 Antineoplastic Agents, Hormonal Phase 4
42 Gastrointestinal Agents Phase 4
43 Antiemetics Phase 4
44 Ophthalmic Solutions Phase 4
45 Lubricant Eye Drops Phase 4
46 Anesthetics Phase 4
47 cefuroxime axetil Phase 4
48 Carotenoids Phase 4
49 Pharmaceutical Solutions Phase 4
50 Adrenergic alpha-Agonists Phase 4

Interventional clinical trials:

(show top 50) (show all 758)
# Name Status NCT ID Phase Drugs
1 Semi-Automated Patterned Laser Trabeculoplasty Unknown status NCT00804323 Phase 4
2 A Prospective, Randomized Evaluation of Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost Ophthalmic Solution 0.004% Unknown status NCT01444040 Phase 4 Travoprost
3 A Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medications (One a Prostaglandin) Treated With Two Trabecular Micro-bypass Stents (iStent Inject) and a Postoperative Topical Prostaglandin Unknown status NCT02873806 Phase 4 Topical travoprost;Tobramycin;Dexamethasone
4 A Prospective Evaluation of Open-angle Glaucoma Subjects on One Topical Hypotensive Medication (Prostaglandin) Treated With Two Trabecular Micro-bypass Stents (iStent Inject) Unknown status NCT02868190 Phase 4
5 A Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medication Treated With One Suprachoroidal Stent Unknown status NCT01252914 Phase 4
6 Impact of Timolol/Dorzolamide Therapy on Autoregulation in Glaucoma Patients Unknown status NCT02053298 Phase 4 Timolol & Dorzolamide
7 A Study of the Glaukos Trabecular Micro-bypass Stent in Open Angle Glaucoma Subjects 1 Stent Versus 2 Stents Unknown status NCT00326079 Phase 4
8 A Prospective Evaluation of Mild to Moderate Open-Angle Glaucoma Subjects With Cataract Treated With Cataract Surgery Plus One Trabecular Micro-bypass Stent and One Suprachoroidal Stent Unknown status NCT03255785 Phase 4
9 Phase 4 Study to Evaluate Efficacy And Safety of Three Different Preparations of Latanoprost 0,005% Eyedrops in Subjects Affected by Primary Open Angle Glaucoma Unknown status NCT01580254 Phase 4 IOPIZE© Latanoprost eyedrops;GALAXIA© Latanoprost eyedrops;Latanoprost RATIOPHARM© latanoprost eyedrops
10 An 8 Week Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Open Angle Glaucoma Unknown status NCT02792803 Phase 4 Xalatan;Apo-Latanoprost;Co-Latanoprost
11 A Prospective, Randomized, Controlled Study to Assess Efficacy,Safety, and Tolerability of Selective Laser Trabeculoplasty vs. Pattern Laser Trabeculoplasty in Patients With Open-angle Glaucoma Unknown status NCT02231515 Phase 4
12 Examination of Ocular Surface Effects With Administration of TRAVATAN Z® and XALATAN® Completed NCT00798759 Phase 4 Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®);Latanoprost ophthalmic solution 0.005% (XALATAN®)
13 A Single Dose Comfort Comparison of Travatan Z in One Eye Versus Xalatan in the Opposite Eye in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Completed NCT00527592 Phase 4 Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®);Latanoprost ophthalmic solution 0.005% (XALATAN®)
14 Prospective, Randomized, Single-Center Study to Evaluate 24-hour Intraocular Pressure Control With Brinzolamide 1%/Brimonidine 0.2% Fixed Dose Combination Therapy Completed NCT01978600 Phase 4 Brinzolamide 1%/Brimonidine 0.2% ophthalmic suspension;Timolol Maleate 0.5%
15 Ocular Surface Conditions in Asian Glaucoma Patients With Existing Corneal Disorders Switching From Preserved Prostaglandin Analogues Monotherapy to Preservative-free Tafluprost Completed NCT04654611 Phase 4 preservative free tafluprost 0.0015%
16 Efficacy and Tolerability of Preservative-free 0.0015% Tafluprost in Glaucoma Patients Completed NCT03104621 Phase 4 Benzalkonium chloride (BAK);0.0015% tafluprost
17 Health-Related Quality of Life in Two Pathways for Newly Diagnosed Open Angle Glaucoma and Ocular Hypertension: an Unmasked, Multi-centre, Randomised Controlled Trial of Initial Selective Laser Trabeculoplasty Versus Medical Therapy Completed NCT03395535 Phase 4 Primary Medical Treatment Pathway
18 A Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medication Treated With Two Trabecular Micro-bypass Stents Completed NCT01252888 Phase 4
19 Comparative Evaluation of Intraocular Pressure During the 24 Hour in Patients Affected by Primary Open-angle Glaucoma and Ocular Hypertension: Latanoprost 0.005% Versus Tafluprost 0.0015% Ophthalmic Solutions Completed NCT01162603 Phase 4 TAFLUPROST 0.0015% EYEDROPS;LATANOPROST 0.005% EYEDROPS
20 Multi-Center Study Comparing Efficacy and Tolerability of TRAVATAN® BAK-free (0.004% Travoprost) in Patients Previously on Latanoprost Ophthalmic Solution 0.005% Monotherapy Completed NCT01510145 Phase 4 Travoprost 0.004% BAK-free
21 A Prospective, Randomized Evaluation of Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent) or Travoprost Ophthalmic Solution 0.004% Completed NCT01443988 Phase 4 Travoprost
22 Dose, Effects and Characteristics of Pilocarpine Completed NCT00803803 Phase 4 Pilocarpine Concentration;Pilocarpine Frequency
23 Adherence of Patients Using Travalert® for Instillation of a Fixed Combination of Travoprost 0.004%/Timolol 0.5% Compared to a Concomitant Regimen of Travoprost 0.004% and Timolol 0.5% Completed NCT00508469 Phase 4 Travoprost 0.004%/timolol 0.5% fixed combination eye drops (DuoTrav);Travoprost 0.004% eye drops;Timolol 0.05% eye drops
24 Additive Effect of Twice Daily Brinzolamide 1%/Brimonidine 0.2% Fixed Dose Combination as an Adjunctive Therapy to a Prostaglandin Analogue Completed NCT02419508 Phase 4 Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension;Brinz/brim vehicle;Prostaglandin analogue
25 ELAZOP Switching Study in Korea Completed NCT01055366 Phase 4 Elazop (Azarga)
26 A Prospective Evaluation of Open-angle Glaucoma Subjects on One Topical Hypotensive Medication Treated With Two Trabecular Micro-bypass Stents Completed NCT01252862 Phase 4
27 Phase IV Randomised Double-masked Clinical Trial: Assessing Morning Versus Evening Dosing of a Fixed Dose Combination of Travoprost 0.004% / Timolol Maleate 0.5% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension Completed NCT00759239 Phase 4 Travoprost 0.004% / Timolol maleate 0.5%;Travoprost 0.004% / Timolol maleate 0.5%
28 Comparison of Brimonidine 0.15% Purite, Dorzolamide 2%, and Brinzolamide 1% as Adjunctive Therapy to Prostaglandin Analogs Completed NCT00675207 Phase 4 Brimonidine purite 0.15%;Dorzolamide 2%;Brinzolamide 1%
29 DuoTrav® Eye Drops As Replacement Therapy Program Completed NCT00828906 Phase 4 DuoTrav
30 Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension Completed NCT00822081 Phase 4 brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination;dorzolamide hcl 2%/ timolol maleate 0.5% fixed combination;brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy.;dorzolamide hcl 2%/timolol maleate 0.5% fixed combinatin as adjunctive to current prostaglandin therapy.
31 Assessing the Efficacy and Tolerability of Changing to DUOTRAV® (Travoprost 0.004%/Timolol 0.5% BAK-Free Fixed Combination), as Replacement Therapy in Patients Previously on Bimatoprost 0.03%/Timolol 0.5% Therapy (Fixed or Unfixed) Completed NCT01327599 Phase 4 Travoprost 0.004%+Timolol 0.5% ophthalmic solution
32 Phase 4 Study to Evaluate Efficacy And Safety of Pneumatic Trabeculoplasty (PNT) in Subjects Affected by Primary Open Angle Glaucoma Completed NCT01540331 Phase 4
33 Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues Completed NCT00539526 Phase 4 Bimatoprost 0.03%;travoprost 0.004%;latanoprost 0.005% eye drops
34 Ologen Collagen Matrix Safety and Effective Comparison With Mitomycin-C(MMC) in Glaucoma Surgery Completed NCT00538590 Phase 4 Mitomycin-C(MMC) and glaucoma filtering surgery
35 Central Corneal Thickness and 24-hour Fluctuation of Intraocular Pressure Completed NCT00941525 Phase 4 Latanoprost
36 A 12 Week Comparison of DuoTrav and Xalacom at 24 Hours Post-Dose in the Treatment of Open-Angle Glaucoma (the DVX Study) Completed NCT00887029 Phase 4 DuoTrav (travoprost-timolol ophthalmic drops);Xalacom (latanoprost-timolol ophthalmic drops)
37 Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension Completed NCT00822055 Phase 4 brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination;dorzolamide hcl 2%/timolol maleate 0.5% fixed combination;brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy;dorzolamide hcl 2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy
38 Patient Preference Comparison of AZARGA Versus COSOPT in Patients With Open-Angle Glaucoma or Ocular Hypertension Completed NCT01340014 Phase 4 Brinzolamide 1.0% + Timolol 0.5% ophthalmic suspension;Dorzolamide 2.0% + Timolol 0.5% ophthalmic solution
39 The Efficacy and Safety of Brinzolamide 1%/Timolol 0.5% Fixed Combination Versus Dorzolamide 1%/Timolol 0.5% in Patients With Open-Angle Glaucoma and Ocular Hypertension Completed NCT02325518 Phase 4 Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension;Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution;Subject's habitual PGA monotherapy
40 Prospective, Randomized, Multi-Center Study to Evaluate the Efficacy and Tolerability of DuoTrav® in Patients Previously Uncontrolled on a Beta-blocker Completed NCT02003391 Phase 4 Beta-blocker monotherapy;Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution
41 Post Market Multicentric Evaluation of the AqueSys XEN Implant in Moderate Primary Open Angle Glaucoma Subjects Completed NCT02006693 Phase 4
42 An Open, Non-randomized Pilot Study on the Effect of Preservative Free Tafluprost (Saflutan® Augentropfen) in Patients With Ocular Hypertension or Primary Open Angle Glaucoma With an Uncontrolled Intraocular Pressure of 30 mmHg and More Completed NCT01979913 Phase 4 Saflutan® 15 microgram/ml Augentropfen im Einzeldosisbehältnis
43 24-Hour Intraocular Pressure (IOP) And Blood Pressure Control In Glaucoma And Ocular Hypertension Patients Completed NCT00330577 Phase 4 timolol maleate 0.5%;latanoprost/timolol fixed combination;placebo (artificial tears)
44 A Study of the Glaukos Trabecular Micro-Bypass Stent in Refractory Open Angle Glaucoma Subjects. Completed NCT00326040 Phase 4
45 Cosopt Versus Xalatan Completed NCT00273429 Phase 4 timolol maleate 0.5%;dorzolamide/timolol maleate fixed combination;latanoprost 0.005%;placebo
46 Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01% and Lumigan® 0.03% Unit Dose, in Patients With Primary Open Angle Glaucoma or Ocular Hypertension, Stabilized by Lumigan® 0.01% With Ocular Surface Intolerance Completed NCT02017327 Phase 4 Monoprost;Lumigan 0.01%;Lumigan 0.03% Unit Dose
47 24-hour IOP-lowering Effect of Brimonidine 0.1% Completed NCT00457795 Phase 4 brimonidine 0.1% (Alphagan® P)
48 24-hour IOP With DTFC and LTFC Monotherapies and the Adjunctive Therapy of DTFC and Latanoprost in Open-angle Glaucoma Insufficiently Controlled With Latanoprost Monotherapy. Completed NCT00397241 Phase 4 Drug: dorzolamide/timolol;Drug: latanoprost/timolol;dorzolamide/timolol and latanoprost;placebo (artificial tears)
49 A Multiple-Dose Study of the IOP-Lowering Efficacy of Azopt 1.0% Compared to Timolol 0.5% When Added to a PGA as Adjunctive Therapy Over a 24 Hour Period in Patients With Glaucoma or Ocular Hypertension Completed NCT00300079 Phase 4 brinzolamide 1.0%
50 Cosopt Versus Xalacom Completed NCT00273481 Phase 4 dorzolamide 2%/timolol maleate 0.5% fixed combination;latanoprost 0.005%/timolol maleate 0.5% fixed combination;timolol maleate 0.5%;placebo

Search NIH Clinical Center for Open-Angle Glaucoma

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Betaxolol
Betaxolol Hydrochloride
bimatoprost
brimonidine
Brimonidine tartrate
brinzolamide
Carteolol
Carteolol Hydrochloride
Dipivefrin
Dipivefrin hydrochloride
dorzolamide
Dorzolamide hydrochloride
Echothiophate Iodide
Epinephrine
epinephrine bitartrate
epinephrine hydrochloride
epinephryl borate
isopropyl unoprostone
latanoprost
Levobunolol
Levobunolol Hydrochloride
Methazolamide
Metipranolol
Metipranolol hydrochloride
Phenylephrine
Phenylephrine bitartrate
Phenylephrine Hydrochloride
Phenylephrine Tannate
Racepinephrine Hydrochloride
Timolol
Timolol Hemihydrate
Timolol Maleate
travoprost
UNOPROSTONE

Cochrane evidence based reviews: glaucoma, open-angle

Genetic Tests for Open-Angle Glaucoma

Anatomical Context for Open-Angle Glaucoma

MalaCards organs/tissues related to Open-Angle Glaucoma:

40
Eye, Retina, Endothelial, Brain, Heart, Kidney, Skin

Publications for Open-Angle Glaucoma

Articles related to Open-Angle Glaucoma:

(show top 50) (show all 12344)
# Title Authors PMID Year
1
Mutations of optineurin in amyotrophic lateral sclerosis. 61 6 54
20428114 2010
2
Lack of association between optineurin gene variants T34T, E50K, M98K, 691_692insAG and R545Q and primary open angle glaucoma in Brazilian patients. 6 61 54
19172505 2009
3
Role of MYOC and OPTN sequence variations in Spanish patients with primary open-angle glaucoma. 6 61 54
17615537 2007
4
Myocilin variants in Indian patients with open-angle glaucoma. 61 6 54
17562996 2007
5
CYP1B1 mutations in French patients with early-onset primary open-angle glaucoma. 61 54 6
15342693 2004
6
Adult-onset primary open-angle glaucoma caused by mutations in optineurin. 6 54 61
11834836 2002
7
MYOC mutation frequency in primary open-angle glaucoma patients from Western Switzerland. 54 6 61
11803488 2001
8
Evidence for genetic heterogeneity within eight glaucoma families, with the GLC1A Gln368STOP mutation being an important phenotypic modifier. 61 6 54
11535458 2001
9
Myocilin Gln368stop mutation and advanced age as risk factors for late-onset primary open-angle glaucoma. 6 61 54
10815160 2000
10
A novel mutation in the GLC1A gene causes juvenile open-angle glaucoma in 4 families from the Italian region of Puglia. 54 6 61
9639450 1998
11
Rare variants in optic disc area gene CARD10 enriched in primary open-angle glaucoma. 6 61
27896285 2016
12
Cellular processing of myocilin. 6 61
24732711 2014
13
Low prevalence of myocilin mutations in an African American population with primary open-angle glaucoma. 6 61
22933836 2012
14
Compound heterozygote myocilin mutations in a pedigree with high prevalence of primary open-angle glaucoma. 61 6
23304066 2012
15
Variable clinical spectrum of the myocilin Gln368X mutation in a Dutch family with primary open angle glaucoma. 61 6
20021252 2010
16
Variation in optineurin (OPTN) allele frequencies between and within populations. 61 6
17293779 2007
17
Myocilin analysis by DHPLC in French POAG patients: increased prevalence of Q368X mutation. 61 6
12872267 2003
18
Founder TIGR/myocilin mutations for glaucoma in the Québec population. 61 6
12189160 2002
19
Rapid mutation detection by the transgenomic wave analyser DHPLC identifies MYOC mutations in patients with ocular hypertension and/or open angle glaucoma. 6 61
11815346 2002
20
Identification of a gene that causes primary open angle glaucoma. 6 61
9005853 1997
21
OPTN 691_692insAG is a founder mutation causing recessive ALS and increased risk in heterozygotes. 6
26740678 2016
22
Mutations in CYP1B1 cause primary congenital glaucoma by reduction of either activity or abundance of the enzyme. 6
18470941 2008
23
Heterozygous expression of myocilin glaucoma mutants increases secretion of the mutant forms and reduces extracellular processed myocilin. 6
19023451 2008
24
Little evidence for association of the glaucoma gene MYOC with open-angle glaucoma. 54 61
20447966 2010
25
Major LOXL1 risk allele is reversed in exfoliation glaucoma in a black South African population. 54 61
20431720 2010
26
Adenoviral gene transfer of active human transforming growth factor-{beta}2 elevates intraocular pressure and reduces outflow facility in rodent eyes. 61 54
19959644 2010
27
Mutation spectrum of the CYP1B1 gene for congenital glaucoma in the Japanese population. 61 54
20151268 2010
28
Functional analysis of CYP1B1 mutations and association of heterozygous hypomorphic alleles with primary open-angle glaucoma. 61 54
19793111 2010
29
New mutation in the MYOC gene and its association with primary open-angle glaucoma in a Chinese family. 61 54
19688280 2010
30
Myocilin in the trabecular meshwork of eyes with primary open-angle glaucoma. 61 54
19662433 2009
31
A novel optineurin genetic mutation associated with open-angle glaucoma in a Chinese family. 61 54
19710941 2009
32
Correction of the disease phenotype of myocilin-causing glaucoma by a natural osmolyte. 61 54
19234343 2009
33
Glaucoma-associated myocilin: a better understanding but much more to learn. 54 61
18804106 2009
34
Genetic risk for primary open-angle glaucoma determined by LMX1B haplotypes. 61 54
18952915 2009
35
Optineurin and its mutants: molecules associated with some forms of glaucoma. 54 61
19672125 2009
36
Different WDR36 mutation pattern in Chinese patients with primary open-angle glaucoma. 54 61
19347049 2009
37
Multiple gene polymorphisms analysis revealed a different profile of genetic polymorphisms of primary open-angle glaucoma in northern Chinese. 61 54
19145250 2009
38
[Matrix metalloproteinases (MMPs): modern molecular markers of open-angle glaucoma diagnosis and therapy]. 61 54
19002081 2008
39
Elevated amounts of myocilin in the aqueous humor of transgenic mice cause significant changes in ocular gene expression. 61 54
18602390 2008
40
Two novel myocilin mutations in a Chinese family with primary open-angle glaucoma. 54 61
18776955 2008
41
Lack of association between LOXL1 variants and primary open-angle glaucoma in three different populations. 61 54
18421074 2008
42
Lysyl oxidase-like 1 gene polymorphisms in Japanese patients with primary open angle glaucoma and exfoliation syndrome. 54 61
18636115 2008
43
Seed-based systematic discovery of specific transcription factor target genes. 54 61
18485006 2008
44
Gene expression profiles of human trabecular meshwork cells induced by triamcinolone and dexamethasone. 54 61
18436822 2008
45
Transgenic mice expressing the Tyr437His mutant of human myocilin protein develop glaucoma. 61 54
18436825 2008
46
Leu432Val polymorphism in CYP1B1 as a susceptible factor towards predisposition to primary open-angle glaucoma. 61 54
18483560 2008
47
Presence of myocilin sequence variants in Japanese patients with open-angle glaucoma. 54 61
18334962 2008
48
Glutathione S-transferase M1 and T1 polymorphisms in Arab glaucoma patients. 61 54
18334963 2008
49
Absence of optineurin (OPTN) gene mutations in Taiwanese patients with juvenile-onset open-angle glaucoma. 54 61
18385781 2008
50
Myocilin allele-specific glaucoma phenotype database. 61 54
17966125 2008

Variations for Open-Angle Glaucoma

ClinVar genetic disease variations for Open-Angle Glaucoma:

6 (show top 50) (show all 141)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 MYOC NM_000261.2(MYOC):c.1111T>C (p.Tyr371His) SNV Pathogenic 242274 rs878854408 GRCh37: 1:171605469-171605469
GRCh38: 1:171636329-171636329
2 OPTN and overlap with 2 gene(s) NC_000010.11:g.(?_13109103)_(13136886_?)del Deletion Pathogenic 529764 GRCh37: 10:13151103-13178886
GRCh38: 10:13109103-13136886
3 LOC108903148 , OPTN NM_001008212.2(OPTN):c.158_161dup (p.Lys55fs) Duplication Pathogenic 576203 rs1564354968 GRCh37: 10:13151279-13151280
GRCh38: 10:13109279-13109280
4 overlap with 4 genes NC_000010.11:g.(?_13109123)_(13183100_?)del Deletion Pathogenic 583651 GRCh37: 10:13151123-13225100
GRCh38: 10:13109123-13183100
5 overlap with 3 genes NC_000010.10:g.(?_12833157)_(13178866_?)del Deletion Pathogenic 584050 GRCh37: 10:12833157-13178866
GRCh38:
6 OPTN NM_001008212.2(OPTN):c.381_382insAG (p.Asp128fs) Insertion Pathogenic 647662 rs774258585 GRCh37: 10:13154464-13154465
GRCh38: 10:13112464-13112465
7 OPTN NC_000010.11:g.(?_13116257)_(13116350_?)del Deletion Pathogenic 831344 GRCh37: 10:13158257-13158350
GRCh38:
8 OPTN NC_000010.11:g.(?_13109113)_(13112645_?)del Deletion Pathogenic 832940 GRCh37: 10:13151113-13154645
GRCh38:
9 CYP1B1 NM_000104.3(CYP1B1):c.241T>A (p.Tyr81Asn) SNV Pathogenic 7744 rs9282671 GRCh37: 2:38302291-38302291
GRCh38: 2:38075148-38075148
10 LTBP2 NM_000428.3(LTBP2):c.1484G>A (p.Arg495Gln) SNV Likely pathogenic 126950 rs137854858 GRCh37: 14:75017969-75017969
GRCh38: 14:74551266-74551266
11 LTBP2 NM_000428.3(LTBP2):c.3571G>A (p.Glu1191Lys) SNV Likely pathogenic 126954 rs137854862 GRCh37: 14:74975388-74975388
GRCh38: 14:74508685-74508685
12 LTBP2 NM_000428.3(LTBP2):c.4250A>G (p.Gln1417Arg) SNV Likely pathogenic 126955 rs137854863 GRCh37: 14:74971805-74971805
GRCh38: 14:74505102-74505102
13 LTBP2 NM_000428.3(LTBP2):c.4912G>A (p.Val1638Met) SNV Likely pathogenic 126958 rs137854860 GRCh37: 14:74969614-74969614
GRCh38: 14:74502911-74502911
14 MYOC NM_000261.2(MYOC):c.1102C>T (p.Gln368Ter) SNV Likely pathogenic 7949 rs74315329 GRCh37: 1:171605478-171605478
GRCh38: 1:171636338-171636338
15 CARD10 NM_014550.4(CARD10):c.1210C>T (p.Arg404Trp) SNV risk factor 224915 rs750643216 GRCh37: 22:37902372-37902372
GRCh38: 22:37506365-37506365
16 CARD10 NM_014550.4(CARD10):c.635G>A (p.Arg212His) SNV risk factor 224912 rs1057519378 GRCh37: 22:37912044-37912044
GRCh38: 22:37516037-37516037
17 CARD10 NM_014550.4(CARD10):c.2485C>T (p.Arg829Trp) SNV risk factor 224916 rs201794655 GRCh37: 22:37888801-37888801
GRCh38: 22:37492794-37492794
18 CARD10 NM_014550.4(CARD10):c.983C>T (p.Ala328Val) SNV risk factor 224913 rs139006752 GRCh37: 22:37904616-37904616
GRCh38: 22:37508609-37508609
19 CARD10 NM_014550.4(CARD10):c.1024G>A (p.Val342Met) SNV risk factor 224914 rs200148764 GRCh37: 22:37904575-37904575
GRCh38: 22:37508568-37508568
20 OPTN NM_001008212.2(OPTN):c.1634G>A (p.Arg545Gln) SNV Conflicting interpretations of pathogenicity 7098 rs75654767 GRCh37: 10:13178766-13178766
GRCh38: 10:13136766-13136766
21 OPTN NM_001008212.2(OPTN):c.425A>C (p.Gln142Pro) SNV Uncertain significance 299211 rs757411888 GRCh37: 10:13154508-13154508
GRCh38: 10:13112508-13112508
22 OPTN NM_001008212.2(OPTN):c.*461G>A SNV Uncertain significance 299230 rs541250740 GRCh37: 10:13179327-13179327
GRCh38: 10:13137327-13137327
23 OPTN NM_001008212.2(OPTN):c.*413G>A SNV Uncertain significance 299229 rs886046825 GRCh37: 10:13179279-13179279
GRCh38: 10:13137279-13137279
24 WDR36 NM_139281.2(WDR36):c.*1061del Deletion Uncertain significance 350363 rs886059771 GRCh37: 5:110463641-110463641
GRCh38: 5:111127943-111127943
25 OPTN NM_001008212.2(OPTN):c.*152G>T SNV Uncertain significance 299224 rs886046823 GRCh37: 10:13179018-13179018
GRCh38: 10:13137018-13137018
26 OPTN NM_001008212.2(OPTN):c.961A>T (p.Ser321Cys) SNV Uncertain significance 299217 rs886046820 GRCh37: 10:13166073-13166073
GRCh38: 10:13124073-13124073
27 WDR36 NM_139281.2(WDR36):c.1810A>G (p.Ile604Val) SNV Uncertain significance 350319 rs34661294 GRCh37: 5:110446903-110446903
GRCh38: 5:111111204-111111204
28 OPTN NM_001008212.2(OPTN):c.-272G>T SNV Uncertain significance 299204 rs886046817 GRCh37: 10:13142194-13142194
GRCh38: 10:13100194-13100194
29 WDR36 NM_139281.2(WDR36):c.*3598_*3602del Deletion Uncertain significance 350407 rs886059792 GRCh37: 5:110466176-110466180
GRCh38: 5:111130478-111130482
30 OPTN NM_001008212.2(OPTN):c.1427A>G (p.His476Arg) SNV Uncertain significance 299220 rs886046821 GRCh37: 10:13174092-13174092
GRCh38: 10:13132092-13132092
31 WDR36 NM_139281.2(WDR36):c.*1044_*1045insG Insertion Uncertain significance 350361 rs886059770 GRCh37: 5:110463625-110463626
GRCh38: 5:111127927-111127928
32 OPTN NM_001008212.2(OPTN):c.*1089G>A SNV Uncertain significance 299235 rs758812707 GRCh37: 10:13179955-13179955
GRCh38: 10:13137955-13137955
33 LOC108903148 , OPTN NM_001008212.2(OPTN):c.247C>T (p.Arg83Cys) SNV Uncertain significance 299209 rs756622651 GRCh37: 10:13152354-13152354
GRCh38: 10:13110354-13110354
34 OPTN NM_001008212.2(OPTN):c.1243-13G>A SNV Uncertain significance 299219 rs374144660 GRCh37: 10:13169732-13169732
GRCh38: 10:13127732-13127732
35 WDR36 NM_139281.2(WDR36):c.1885-20_1885-14delinsATATATATA Indel Uncertain significance 350323 rs886059764 GRCh37: 5:110448753-110448759
GRCh38: 5:111113054-111113060
36 OPTN NM_001008212.2(OPTN):c.-250C>A SNV Uncertain significance 299206 rs886046818 GRCh37: 10:13142216-13142216
GRCh38: 10:13100216-13100216
37 WDR36 NM_139281.2(WDR36):c.*2644del Deletion Uncertain significance 350391 rs747448169 GRCh37: 5:110465224-110465224
GRCh38: 5:111129526-111129526
38 OPTN NM_001008212.2(OPTN):c.*1042T>G SNV Uncertain significance 299233 rs886046827 GRCh37: 10:13179908-13179908
GRCh38: 10:13137908-13137908
39 WDR36 NM_139281.2(WDR36):c.*1040_*1050del Deletion Uncertain significance 350359 rs532039350 GRCh37: 5:110463617-110463627
GRCh38: 5:111127919-111127929
40 OPTN NM_001008212.2(OPTN):c.*1285T>C SNV Uncertain significance 299237 rs560947786 GRCh37: 10:13180151-13180151
GRCh38: 10:13138151-13138151
41 OPTN NM_001008212.2(OPTN):c.*386C>A SNV Uncertain significance 299228 rs745564491 GRCh37: 10:13179252-13179252
GRCh38: 10:13137252-13137252
42 WDR36 NM_139281.2(WDR36):c.*2282_*2284delCTT Microsatellite Uncertain significance 350385 rs886059780 GRCh37: 5:110464860-110464862
GRCh38: 5:111129162-111129164
43 OPTN NM_001008212.2(OPTN):c.*306G>A SNV Uncertain significance 299227 rs538280633 GRCh37: 10:13179172-13179172
GRCh38: 10:13137172-13137172
44 WDR36 NM_139281.2(WDR36):c.1885-20_1885-14delinsATATATATATA Indel Uncertain significance 350324 rs886059764 GRCh37: 5:110448753-110448759
GRCh38: 5:111113054-111113060
45 LTBP2 NM_000428.3(LTBP2):c.4356G>A (p.Pro1452=) SNV Uncertain significance 126956 rs137854865 GRCh37: 14:74971699-74971699
GRCh38: 14:74504996-74504996
46 LTBP2 NM_000428.3(LTBP2):c.4668G>C (p.Pro1556=) SNV Uncertain significance 126957 rs137854866 GRCh37: 14:74970224-74970224
GRCh38: 14:74503521-74503521
47 OPTN NM_001008211.1(OPTN):c.-453G>T SNV Uncertain significance 299200 rs886046816 GRCh37: 10:13142082-13142082
GRCh38: 10:13100082-13100082
48 WDR36 NM_139281.2(WDR36):c.99C>G (p.Asp33Glu) SNV Uncertain significance 262467 rs35629723 GRCh37: 5:110428085-110428085
GRCh38: 5:111092387-111092387
49 OPTN NM_001008212.2(OPTN):c.*1063C>A SNV Uncertain significance 299234 rs530046832 GRCh37: 10:13179929-13179929
GRCh38: 10:13137929-13137929
50 WDR36 NM_139281.2(WDR36):c.2706+8_2706+11dup Duplication Uncertain significance 350336 rs886059766 GRCh37: 5:110461500-110461501
GRCh38: 5:111125802-111125803

Expression for Open-Angle Glaucoma

Search GEO for disease gene expression data for Open-Angle Glaucoma.

Pathways for Open-Angle Glaucoma

Pathways related to Open-Angle Glaucoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.09 TGFB2 OPTC MMP1 LTBP2 LOXL1 ELN
2
Show member pathways
10.79 TGFB2 LTBP2 LOXL1 ELN

GO Terms for Open-Angle Glaucoma

Cellular components related to Open-Angle Glaucoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 collagen-containing extracellular matrix GO:0062023 9.35 TGFB2 MYOC LTBP2 LOXL1 ELN
2 extracellular matrix GO:0031012 9.02 OPTC MMP1 LTBP2 LOXL1 ELN

Biological processes related to Open-Angle Glaucoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 visual perception GO:0007601 9.46 WDR36 OPA1 CYP1B1 CRYAA
2 positive regulation of xenophagy GO:1904417 8.96 TBK1 OPTN
3 collagen fibril organization GO:0030199 8.92 TGFB2 OPTC LOXL1 CYP1B1

Molecular functions related to Open-Angle Glaucoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular matrix structural constituent GO:0005201 8.8 OPTC LTBP2 ELN

Sources for Open-Angle Glaucoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....